--NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy, will be showcased in the fourth of a four-part series titled the “Explorer Series”--
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here